GlassScriptPhysician profile
Kenneth Irwin Fink
NPI 1205817558
$3,792.95
in general payments reported to CMS, 2019-2025
36 companies · $850 in 2025
The $850 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $154 · 2021: $572 · 2022: $96.16 · 2023: $369 · 2024: $612 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.94 |
| Education | $277.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $523.39 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Daiichi Sankyo INC. | $410.32 | 2023-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $364.89 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genentech USA, INC. | $349.27 | 2019-2025 | Venclexta, Gazyva, Itovebi |
| Novartis Pharmaceuticals Corporation | $183.22 | 2019-2025 | |
| Pfizer INC. | $182.93 | 2019-2025 | |
| Genzyme Corporation | $161.71 | 2019 | |
| Celgene Corporation | $157.50 | 2023-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $152.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $136.39 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2024 | Nuzyra |
| Seagen INC. | $116.63 | 2019 | |
| Boston Scientific Corporation | $100.00 | 2021 | |
| Incyte Corporation | $99.99 | 2021 | |
| Exelixis INC. | $86.34 | 2019-2025 | Cabometyx |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.